Former Chief Research Officer and Former Chief Executive Officer · Olema Pharmaceuticals, Inc. (OLMA)

Cyrus Harmon

A named executive officer of Olema Pharmaceuticals in every fiscal year CompBrief holds from FY2019 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$1,334,830

Salary $120,972

FY2020: $3,976,890

3rd of 4 named executive officers at Olema Pharmaceuticals by FY2023 total.

4 named officers on file for Olema Pharmaceuticals, FY2023

Cyrus Harmon’s pay file — $29

  • 3 fiscal years of pay, line by line
  • 2 equity grants, each cited to its filing
  • OLMA’s disclosed peer group of 28 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Olema Pharmaceuticals’s whole pay program stands against its peers

  • Olema Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on OLMA→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 26, 2024 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Cyrus Harmon’s full pay file as a PDF — free

More than this page: up to 10 years of Cyrus’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Cyrus Harmon compensation by year

Olema Pharmaceuticals Summary Compensation Table · all 3 fiscal years held
In US dollars, as Olema Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2019FY2020FY2023
Salary$300,000$395,833$120,972
Bonus$0$0—
Stock awards—$344,046—
Option awards—$2,974,853$550,180
Non-equity incentive—$262,158$48,000
Pension and deferred compensation$0$0$0
All other$0$0$615,678
Total$300,000$3,976,890$1,334,830

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Olema Pharmaceuticals, Inc. DEF 14A filed April 26, 2024, accession 0000950170-24-049287, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Olema Pharmaceuticals, Inc. filed document, accession 0000950170-24-049287. Every figure is read from that document and cited to the page and table it appears in. Filed April 26, 2024.

$300K
$4.0M
$1.3M
FY19
FY20
FY23
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
PSU29,250$410,378—
RSU17,934$251,614—
Option41,099—$19.00
Option150,000—$4.87
Option150,000—$4.87
Option42,724—$4.82
Option56,605—$7.02

Per the Outstanding Equity Awards at Fiscal Year-End table in Olema Pharmaceuticals, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

11 Form 4 lines since the FY2023 proxy (filed April 26, 2024)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-07-24Sale—12,500$11.71702,770
2026-07-23Sale—12,500$11.58715,270
2026-06-18Grant or award derivative—29,500$0.0029,500
2026-01-20Sale—10,000$26.88727,770
2026-01-14Sale—3,489$29.12737,770
2025-12-22Sale—2,881$28.53741,259
2025-09-18Sale—10,000$8.33744,140
2025-09-18Sale—3,086$8.32117,028

The 8 most recent of 11 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Olema Pharmaceuticals’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Sean BohenPresident and Chief Executive Officer$3,152,370
Shane KovacsChief Operating and Financial Officer$1,548,370
Cyrus Harmon · this pageFormer Chief Research Officer and Former Chief Executive Officer$1,334,830
Naseem ZojwallaChief Medical Officer$1,299,370

Board service

Olema Pharmaceuticals board · FY2024–FY2025
Director compensation in US dollars, as Olema Pharmaceuticals reports it. Most recent year first; a dash means the company reported no figure in that column.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2025$43,750—$65,688—$109,438
FY2024$40,000—$200,790—$240,790

Each year as the company reported it in Olema Pharmaceuticals's director compensation table. Totals are the company's own disclosed totals.

How this board is paid

Company policy: Olema Pharmaceuticals pays directors a $45,000 cash retainer. As stated in Olema Pharmaceuticals's FY2025 proxy.

Committees

Science and Technology

The full Olema Pharmaceuticals compensation record

free company brief

This page is one person within Olema Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Olema Pharmaceuticals proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Olema Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Cyrus Harmon's compensation dossier · One-time report. No refunds.